Open Access

Erratum to: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment

Orphanet Journal of Rare Diseases201611:95

https://doi.org/10.1186/s13023-016-0482-3

Received: 6 July 2016

Accepted: 6 July 2016

Published: 12 July 2016

The original article was published in Orphanet Journal of Rare Diseases 2015 10:125

Erratum

Following the publication of our article “Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment” by Kampmann et al. [1] we have become aware that the dose of agalsidase alfa was not reported.

Eligible patients had a Fabry disease diagnosis confirmed by enzyme assay (males) and/or DNA analysis (males and females), were aged ≥14 years at treatment start, and had received agalsidase alfa (Replagal®; Shire, Lexington, Massachusetts, USA) ERT at a dose of 0.2 mg/kg body weight every other week for approximately 10 years.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Section Head for Congenital Heart Defects, Center for Pediatric and Adolescent Medicine, University Medical Center, University of Mainz
(2)
Statistical Programmer, Rare Diseases Business Unit, Global Outcomes Research, Shire
(3)
Professor Emeritus, Department of Pediatrics, University Medical Center, University of Mainz

Reference

  1. Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment. Orphanet J Rare Dis. 2015;10:125.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement